Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.38 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.37 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.37 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150964 | 1.00 | KMT2A (0.68) | KMT2AMEN1L3MBTL1ALDH1A1BCHE | |
| SCHEMBL7156057 | 1.00 | KMT2A (0.68) | KMT2AMEN1L3MBTL1ALDH1A1BCHE | |
| SCHEMBL16307846 | 1.00 | KMT2A (0.68) | KMT2AMEN1L3MBTL1ALDH1A1BCHE | |
| SCHEMBL13290311 | 1.00 | KMT2A (0.68) | KMT2AMEN1L3MBTL1ALDH1A1BCHE | |
| SCHEMBL7152193 | 1.00 | KMT2A (0.68) | KMT2AMEN1L3MBTL1ALDH1A1BCHE | |
| SCHEMBL7152880 | 1.00 | KMT2A (0.68) | KMT2AMEN1L3MBTL1ALDH1A1BCHE | |
| SCHEMBL19186152 | 1.00 | KMT2A (0.68) | KMT2AMEN1L3MBTL1ALDH1A1BCHE | |
| SCHEMBL7155165 | 1.00 | KMT2A (0.68) | KMT2AMEN1L3MBTL1ALDH1A1BCHE | |
| SCHEMBL22808305 | 1.00 | KMT2A (0.68) | KMT2AMEN1L3MBTL1ALDH1A1BCHE | |
| SCHEMBL6810325 | 0.93 | KMT2A (0.62) | KMT2AMEN1L3MBTL1ALDH1A1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | KMT2A 2838/4885MEN1 3848/4885L3MBTL1 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.